Andrew Han covers breaking news for GenomeWeb. He tracks companies in the molecular biology research and diagnostic markets.
Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
PerkinElmer may be nearing an FDA submission for a panel based on technology from the University of Washington, amid a push for state-mandated screening programs.
Research using the T2Plex instrument has detected a new conformation of red blood cells indicating a tight clot, which could be used as a biomarker.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
Scientists at Memorial Sloan Kettering Cancer Center, led by Gabriela Chiosis, revealed how the complexes are important for tumor survival in certain cases.
Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.